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Abstract 
 
 The first synthesis of the fungal natural product (-)-xylariamide A 1 is reported.  N,O-
bis(trimethylsilyl)acetamide induced coupling of D-tyrosine with (E)-but-2-enedioic acid 2,5-
dioxo-pyrrolidin-1-yl ester methyl ester 5 produced the dechloro natural product 6, which 
was subsequently monochlorinated using oxone and KCl to yield synthetic 1.  (-)-
Xylariamide A 1, (+)-xylariamide A 2 and (-)-dechloroxylariamide A 6 displayed no 
cytotoxic or antimicrobial activity. 
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We have recently reported the isolation and structure elucidation of (-)-xylariamide A 
1 from the plant-associated microfungus, Xylaria sp. (FRR 5657).1  Confirmation of the 
structure and absolute stereochemistry of 1 resulted from the synthesis of (+)-xylariamide A 
2.1  Both (-)-xylariamide A 1 and (+)-xylariamide A 2 were screened for toxicity in a brine 
shrimp (Artemia salina) lethality assay and only the natural product displayed any activity.1  
Only minute quantities (0.9 mg) of the bioactive natural product 1 were initially isolated from 
the large-scale fungal fermentation and this prevented more detailed biological evaluations of 
(-)-xylariamide A.  Total synthesis of the chiral chlorinated fungal metabolite 1 appeared to 
be the best means of obtaining quantities of this compound that would allow a more thorough 
bioactivity profiling.  Herein we report a short and efficient synthesis of (-)-xylariamide A 1 
along with its cytotoxic and antimicrobial screening results. 
 
Our synthetic approach to 1 was based on similar chemistry to that reported for (+)-
xylariamide A 2 where the silylating agent N,O-bis(trimethylsilyl)acetamide (BSA), was used 
to form an amide bond between 3-chloro-L-tyrosine and the N-succinimide activated ester, 
(E)-but-2-enedioic acid 2,5-dioxo-pyrrolidin-1-yl ester methyl ester 5.1,2  A different 
synthetic route for the natural product 1 had to be designed since we could not find a 
commercial supplier for 3-chloro-D-tyrosine.  Rather than synthesise 3-chloro-D-tyrosine we 
decided to react 5 with D-tyrosine in the presence of BSA and follow this coupling reaction 
with the selective monochlorination of the BSA amide product to yield the natural product 1.  
The synthesis of (-)-xylariamide A 1 began with the commercially available (E)-but-2-
enedioic acid dimethyl ester (Scheme 1), selective monohydrolysis of which using aqueous 
LiOH in acetone, afforded the previously reported (E)-but-2-enedioic acid monomethyl ester 
(4, 87% yield).3  Coupling 4 with N-hydroxysuccinimide using EDCI in CH3CN yielded the 
known (E)-but-2-enedioic acid 2,5-dioxo-pyrrolidin-1-yl ester methyl ester (5, 40%).4  (-)-
Dechloroxylariamide A 6 was produced by reacting D-tyrosine, (E)-but-2-enedioic acid 2,5-
dioxo-pyrrolidin-1-yl ester methyl ester 5 and BSA in DMF at 60 °C for 16 h.5  Purification 
was performed using gel permeation chromatography to afford (-)-dechloroxylariamide A (6, 
54% yield).  Monochlorination of 6 using oxone and KCl in aqueous CH3CN,6 followed by 
C18 HPLC chromatography yielded pure (-)-xylariamide A (1, 78%).7  The NMR, MS, UV, 
IR and [α]D data for synthetic 1 were identical to those reported for the natural product (-)-
xylariamide A 1.1 
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(-)-Xylariamide A 1, the previously synthesized (+)-xylariamide A 21 and (-)-
dechloroxylariamide A 6 were all tested for cytotoxicity against the human cancer cell lines 
MCF-7 (breast), H460 (non small cell lung), and SF268 (CNS) using the colourimetric 
sulphorhodamine B assay.8  Compounds 1, 2 and 6 showed no cytotoxicity after 72 h when 
tested at 5 and 50 μg/mL.  Compounds 1, 2 and 6 were also tested against a panel of 
nosocomial microbial strains which included multi-drug resistant Staphylococcus aureus 
(wild type MRSA), Staphylococcus aureus (NCCLS 29523), Escherichia coli (ATCC 
25922), Enterococcus faecalis (NCCLS 29212), Pseudomonas aeruginosa (ATCC 27853), 
Streptococcus pyogenes (ATCC 19615), Acinetobacter anitratus (wild type) and Candida 
albicans (ATCC 60193).  Antimicrobial activities were evaluated using a broth micro 
dilution assay9,10 with each compound screened in a double dilution series from 500 μg/mL to 
1.0 μg /mL.  No microbial growth inhibition was observed at any of these concentrations after 
20 h of dosing. 
 In conclusion, this paper reports a simple synthesis of the fungal natural product (-)-
xylariamide A 1 from readily available starting materials.  (-)-Xylariamide A 1, (+)-
xylariamide A 2 and (-)-dechloroxylariamide A 6 displayed no cytotoxic or antimicrobial 
activity. 
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Figure 1.  Structures for 1 and 2.  
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Scheme 1. Total synthesis of (-)-xylariamide A 1.  Reagents and conditions:  (a) LiOH, acetone, rt, 1 h (87%); 
(b) N-Hydroxysuccinimide, EDCI, CH3CN, rt, 24 h (40%);  (c) D-tyrosine, BSA, DMF, 60 οC, 16 h (54%);  
(d) Oxone, KCl, CH3CN/H2O, rt, 72 h (78%).
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